Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Sjoquist KM, Espinoza D, Mileshkin L, Ananda S, Shannon C, Yip S, Goh J, Bowtell D, Harrison M, Friedlander ML. Sjoquist KM, et al. Among authors: mileshkin l. Gynecol Oncol. 2021 May;161(2):374-381. doi: 10.1016/j.ygyno.2021.02.002. Epub 2021 Feb 23. Gynecol Oncol. 2021. PMID: 33637349 Free article. Clinical Trial.
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma.
Obermair A, Mileshkin L, Bolz K, Kondalsamy-Chennakesavan S, Cheuk R, Vasey P, Wyld D, Goh J, Nicklin JL, Perrin LC, Sykes P, Janda M. Obermair A, et al. Among authors: mileshkin l. Gynecol Oncol. 2011 Feb;120(2):179-84. doi: 10.1016/j.ygyno.2010.10.039. Epub 2010 Dec 3. Gynecol Oncol. 2011. PMID: 21126755 Clinical Trial.
Carboplatin dosing in ovarian cancer: problems and pitfalls.
Collins IM, Roberts-Thomson R, Faulkner D, Rischin D, Friedlander M, Mileshkin L. Collins IM, et al. Among authors: mileshkin l. Int J Gynecol Cancer. 2011 Oct;21(7):1213-8. doi: 10.1097/IGC.0b013e31822127ad. Int J Gynecol Cancer. 2011. PMID: 21705909 Review.
Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer--a population-based study.
Jordan S, Steer C, DeFazio A, Quinn M, Obermair A, Friedlander M, Francis J, O'Brien S, Goss G, Wyld D, Australian Ovarian Cancer Study Group, Webb P; Ovarian Cancer Patterns of Care Study Group. Jordan S, et al. Gynecol Oncol. 2013 May;129(2):310-7. doi: 10.1016/j.ygyno.2013.02.007. Epub 2013 Feb 9. Gynecol Oncol. 2013. PMID: 23403164 Free article.
Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium.
Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, Rossing MA, Terry KL, Wu AH; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Risch HA, Yu H, Doherty JA, Chang-Claude J, Hein R, Nickels S, Wang-Gohrke S, Goodman MT, Carney ME, Matsuno RK, Lurie G, Moysich K, Kjaer SK, Jensen A, Hogdall E, Goode EL, Fridley BL, Vierkant RA, Larson MC, Schildkraut J, Hoyo C, Moorman P, Weber RP, Cramer DW, Vitonis AF, Bandera EV, Olson SH, Rodriguez-Rodriguez L, King M, Brinton LA, Yang H, Garcia-Closas M, Lissowska J, Anton-Culver H, Ziogas A, Gayther SA, Ramus SJ, Menon U, Gentry-Maharaj A, Webb PM; Ovarian Cancer Association Consortium. Olsen CM, et al. Endocr Relat Cancer. 2013 Mar 22;20(2):251-62. doi: 10.1530/ERC-12-0395. Print 2013 Apr. Endocr Relat Cancer. 2013. PMID: 23404857 Free PMC article.
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM; Australian Cancer Study; Australian Ovarian Cancer Study; Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA; Consortium of Investigators of Modifiers of BRCA1/2; Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, Dörk T, du Bois A, Dürst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, Górski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, Høgdall CK, Høgdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levin… See abstract for full author list ➔ Permuth-Wey J, et al. Nat Commun. 2013;4:1627. doi: 10.1038/ncomms2613. Nat Commun. 2013. PMID: 23535648 Free PMC article.
Oral cyclophosphamide in recurrent ovarian cancer.
Handolias D, Quinn M, Foo S, Mileshkin L, Grant P, Dutu G, Rischin D. Handolias D, et al. Among authors: mileshkin l. Asia Pac J Clin Oncol. 2016 Mar;12(1):e154-60. doi: 10.1111/ajco.12074. Epub 2013 May 29. Asia Pac J Clin Oncol. 2016. PMID: 23718870
Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S, Weir BA, Carter S, Gresshoff I, Mileshkin L, Rischin D, Hahn WC, Waring PM, Getz G, Cullinane C, Campbell LJ, Bowtell DD. Etemadmoghadam D, et al. Among authors: mileshkin l. Clin Cancer Res. 2013 Nov 1;19(21):5960-71. doi: 10.1158/1078-0432.CCR-13-1337. Epub 2013 Sep 4. Clin Cancer Res. 2013. PMID: 24004674
295 results